DISCO Pharmaceuticals raises €36.0M Seed round
11 December 2025· Cologne, Germany· health, biotech, proteomics, b2b, deep_hardware
The proceeds will enable DISCO to advance multiple lead antibody-drug conjugate (ADC) candidates in small cell lung cancer (SCLC) and microsatellite-stable colorectal cancer (MSS-CRC) toward IND-enabling studies and expand its pipeline.
Investors
LeadAckermans & van Haaren
Also participating
Sofinnova PartnersM VenturesPanakes PartnersAbbVie VenturesNRW. Bank
About DISCO Pharmaceuticals
Stage
Seed
Headquarters
Cologne, Germany
Founded
2022
Team Size
21–50
Sectors
healthbiotechproteomicsb2bdeep_hardware